301 related articles for article (PubMed ID: 16257308)
21. Moxifloxacin resistance: intrinsic to antibiotic or related to mutation?
Agarwal T; Jhanji V; Satpathy G; Nayak N; Chawla B; Tandon R; Titiyal JS
Optom Vis Sci; 2012 Dec; 89(12):1721-4. PubMed ID: 23142880
[TBL] [Abstract][Full Text] [Related]
22. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.
Kim DH; Stark WJ; O'Brien TP; Dick JD
Ophthalmology; 2005 Nov; 112(11):1992-6. PubMed ID: 16183125
[TBL] [Abstract][Full Text] [Related]
23. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones.
McDonald M; Blondeau JM
J Cataract Refract Surg; 2010 Sep; 36(9):1588-98. PubMed ID: 20692574
[TBL] [Abstract][Full Text] [Related]
24. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
Segreti J; Jones RN; Bertino JS
J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
[TBL] [Abstract][Full Text] [Related]
25. The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.
Benitez-Del-Castillo J; Verboven Y; Stroman D; Kodjikian L
Clin Drug Investig; 2011; 31(8):543-557. PubMed ID: 21604820
[TBL] [Abstract][Full Text] [Related]
26. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens.
Callegan MC; Ramirez R; Kane ST; Cochran DC; Jensen H
Adv Ther; 2003; 20(5):246-52. PubMed ID: 14964344
[TBL] [Abstract][Full Text] [Related]
27. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
Yağci R; Oflu Y; Dinçel A; Kaya E; Yağci S; Bayar B; Duman S; Bozkurt A
Eye (Lond); 2007 Jul; 21(7):990-4. PubMed ID: 16732216
[TBL] [Abstract][Full Text] [Related]
28. Moxifloxacin susceptibility mediates the relationship between causative organism and clinical outcome in bacterial keratitis.
Oldenburg CE; Lalitha P; Srinivasan M; Manikandan P; Bharathi MJ; Rajaraman R; Ravindran M; Mascarenhas J; Nardone N; Ray KJ; Glidden DV; Acharya NR; Lietman TM
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1522-6. PubMed ID: 23385795
[TBL] [Abstract][Full Text] [Related]
29. Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis.
Ray KJ; Prajna L; Srinivasan M; Geetha M; Karpagam R; Glidden D; Oldenburg CE; Sun CQ; McLeod SD; Acharya NR; Lietman TM
JAMA Ophthalmol; 2013 Mar; 131(3):310-3. PubMed ID: 23307105
[TBL] [Abstract][Full Text] [Related]
30. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis.
Parmar P; Salman A; Kalavathy CM; Kaliamurthy J; Prasanth DA; Thomas PA; Jesudasan CA
Am J Ophthalmol; 2006 Feb; 141(2):282-286. PubMed ID: 16458681
[TBL] [Abstract][Full Text] [Related]
31. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
Am J Ophthalmol; 2005 Sep; 140(3):497-504. PubMed ID: 16083841
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial.
Constantinou M; Daniell M; Snibson GR; Vu HT; Taylor HR
Ophthalmology; 2007 Sep; 114(9):1622-9. PubMed ID: 17822972
[TBL] [Abstract][Full Text] [Related]
33. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans.
Chang Lin JE; Welty D
Surv Ophthalmol; 2006; 51(5):530; author reply 530-1. PubMed ID: 16950254
[No Abstract] [Full Text] [Related]
34. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model.
Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
Am J Ophthalmol; 2004 Jul; 138(1):33-7. PubMed ID: 15234279
[TBL] [Abstract][Full Text] [Related]
35. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections.
Mah FS
Curr Opin Ophthalmol; 2004 Aug; 15(4):316-20. PubMed ID: 15232471
[TBL] [Abstract][Full Text] [Related]
36. [In vitro antibiotic susceptibility to fluoroquinolones].
Wong CA; Galvis V; Tello A; Villareal D; Rey JJ
Arch Soc Esp Oftalmol; 2012 Mar; 87(3):72-8. PubMed ID: 22423655
[TBL] [Abstract][Full Text] [Related]
37. Moxifloxacin for bacterial keratitis.
Rosenberg J; Eisen L; Kim J
Ophthalmology; 2008 Jun; 115(6):1103; author reply 1103. PubMed ID: 18519075
[No Abstract] [Full Text] [Related]
38. Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
Sanders ME; Moore QC; Norcross EW; Shafiee A; Marquart ME
J Ocul Pharmacol Ther; 2010 Apr; 26(2):193-8. PubMed ID: 20334537
[TBL] [Abstract][Full Text] [Related]
39. Besifloxacin ophthalmic suspension 0.6%.
Carter NJ; Scott LJ
Drugs; 2010; 70(1):83-97. PubMed ID: 20030427
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of moxifloxacin 0.5% in treatment of nonperforated bacterial corneal ulcers: a randomized controlled trial.
Sharma N; Goel M; Bansal S; Agarwal P; Titiyal JS; Upadhyaya AD; Vajpayee RB
Ophthalmology; 2013 Jun; 120(6):1173-8. PubMed ID: 23415776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
